MARCY L’ÉTOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology ...
Salt Lake City , UT – BioFire Diagnostics, Inc. today announced that it has signed a competitive prototyping contract with the Department of the Army for Increment 1 of the Next Generation Diagnostics ...
SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,394,608 covering the company’s FilmArray ...
The FilmArray ® Ebola test (BioThreat-E test TM) runs on the BioFire FilmArray ® system, a highly accurate and easy-to-use molecular diagnostic instrument which is currently used in hundreds of ...
MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology ...
SALT LAKE CITY, May 2, 2013 /PRNewswire/ -- BioFire Diagnostics, Inc. today announced the expansion of its financing commitment with Athyrium Opportunities Fund to $45 million from $25 million. The ...
MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary ...
BioFire Diagnostics Inc. has raised $25 million in new funding from New York-based Athyrium Opportunities Fund. The money will be used to help commercialize the company’s “FilmArray” diagnostic ...
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris: BIM), a world leader in the field of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results